[Opinion] Should the 90% CI for GMR be required to encompass 1 [RSABE / ABEL]

posted by bebac_fan – US, 2018-03-29 18:57 (2587 d 02:42 ago) – Posting: # 18617
Views: 11,474

Dear John

❝ So basically he's questioning the validity of FDA's 20% window on BE then...


Actually, I am questioning the validity of FDA's Swr scaled 10% window on BE for NTID.

If a GMR of 1.1 is clinically relevant (i.e. a test should be sensitive for this), and the NTID with a Swr of .22 will pass by ABE, this is a failure IMO.

Thanks,
BF

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
105 visitors (0 registered, 105 guests [including 4 identified bots]).
Forum time: 21:40 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5